Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amgen, Inc. (AMGN) vs Celsius Holdings, Inc. (CELH) Price & Performance

Amgen, Inc.
Celsius Holdings, Inc.

Price performance

Price movement over the last 24 hours

Key statistics

Amgen, Inc. vs Celsius Holdings, Inc. — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Celsius Holdings, Inc. trades at $30.64 (market cap $7.82B). The key difference: Amgen, Inc. is far larger — about 25.1× Celsius Holdings, Inc.'s market cap, and Amgen, Inc. pays a 2.77% dividend while Celsius Holdings, Inc. pays none. Which is the better fit depends on your goals.

AMGNCELH
Market Cap
$196.12B$7.82B
Sector
HealthConsumer Staples
52-Week High
$388.16$64.86
52-Week Low
$271.18$27.75
Enterprise Value
$241.41B$9.70B
Dividend Yield
2.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amgen, Inc.

AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.

The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.

Celsius Holdings, Inc.

Celsius Holdings (CELH) trades at $30.60, showing modest daily gains amid a broader bearish technical trend. The stock demonstrates strong fundamental growth with revenue surging from $654M in 2022 to $2.52B in 2025, though net margins compressed to 4.29%. Recent quarters consistently beat EPS estimates, and analyst sentiment remains overwhelmingly bullish with a $53.30 consensus target. However, negative cash flow trends and ongoing legal investigations present headwinds.

CELH offers significant upside potential based on analyst targets and robust revenue expansion, particularly in international markets. Key risks include margin pressure, high valuation multiples, and legal overhangs from shareholder investigations. The stock's investment case hinges on sustaining growth momentum while navigating competitive and operational challenges.

Returns comparison

Trailing returns across standard periods

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Read more on AMGN

About Celsius Holdings, Inc.

Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.

Read more on CELH